This article was originally published in Start Up
A Copenhagen-based company is taking a unique, dual-action approach to tackling osteoporosis.
You may also be interested in...
To some, the osteoporosis space may seem crowded with Big Pharma and Big Biotech drugs already on the market and more waiting in the wings. But it's a huge market with many unmet needs, offering start-ups an opportunity to develop even better, safer, more convenient drugs. In this issue we profile four emerging companies that are intent on creating novel bone-building, not just bone-preserving, drugs for the osteoporosis market.
The University of Wisconsin - Madison spin-off is modifying the vitamin D molecule to enhance its bone building activity for the treatment of osteoporosis.